2-甲基-3-氨基-5-溴吡啶 | 914358-73-9

• 物质功能分类: 医药中间体 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 2-甲基-3-氨基-5-溴吡啶
• 中文别名: 3-氨基-5-溴-2-甲基吡啶；2-甲基-3-氨基-5-溴吡；3-氨基-5-溴-2-甲基-吡啶,2-甲基-3-氨基-5-溴吡啶；2-甲基-3-氨基-5-溴吡啶；3-氨基-5-溴-2-甲基-吡啶；3-氨基-5-溴-2-甲基-吡啶；5-溴-2-甲基-3-氨基吡啶
• 英文名称: 5-bromo-2-methylpyridin-3-ylamine
• 英文别名: 5-bromo-2-methylpyridin-3-amine；2-methyl-3-amino-5-bromopyridine；5-bromo-2-methylpyridine-3-amine
• CAS: 914358-73-9
• 化学式: C₆H₇BrN₂
• 分子量: 187.039
• InChiKey: CBAXYISWNGGXOZ-UHFFFAOYSA-N

物化性质

• 熔点：
  108-109℃
• 沸点：
  283.5±35.0 °C(Predicted)
• 密度：
  1.593±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 安全说明：
  S26,S39
• 危险类别码：
  R41
• 海关编码：
  2933399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  应存于阴凉避光处，并在惰性气体保护下保存。

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
3-Amino-5-bromopicoline
Product Name:
Synonyms: 5-Bromo-2-methylpyridin-3-amine; 3-Amino-5-bromo-2-methylpyridine

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.
H315: Causes skin irritation
H319: Causes serious eye irritation
H335: May cause respiratory irritation
P261: Avoid breathing dust/fume/gas/mist/vapours/spray
Wear protective gloves/protective clothing/eye protection/face protection
P280:
P305+P351+P338: IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses if present
and easy to do – continue rinsing
P304+P340: IF INHALED: Remove victim to fresh air and keep at rest in a position comfortable for breathing
P405: Store locked up

---

Section 3. Composition/information on ingredients.
3-Amino-5-bromopicoline
Ingredient name:
CAS number: 914358-73-9

---

Section 4. First aid measures
Immediately wash skin with copious amounts of water for at least 15 minutes while removing
Skin contact:
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.
Ingestion:

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Storage: Store in closed vessels.

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Not specified
Appearance:
Boiling point: No data
Melting point: No data
Flash point: No data
Density: No data
Molecular formula: C6H7BrN2
Molecular weight: 187

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, hydrogen bromide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

制备方法与用途

用途

氨基吡啶是一种重要精细化工中间体，在医药和农药等领域广泛应用。其中，2-甲基-3-氨基-5-溴吡啶作为mGluR2拮抗剂，可用于治疗中枢神经系统疾病。

制备

将还原铁粉、乙酸及水加入250 mL四口反应瓶中，加热回流15分钟，冷却至85℃后，缓慢加入2-甲基-3-硝基-5-溴吡啶。反应过程中会放热，待加完后继续加热回流1小时，确保反应完全进行。随后，冷却至室温并抽滤，将滤渣用水清洗，合并滤液。

在向滤液中加入保险粉以防止产物被氧化之后，在下一步反应之前通过旋转蒸发得到类白色粉末状的2-甲基-3-氨基-5-溴吡啶。

反应信息

• 作为反应物：
  描述：

  2-甲基-3-氨基-5-溴吡啶 在 1,1'-双(二苯基膦)二茂铁 、 二(氰基苯)二氯化钯 甲醇 、 potassium acetate 、 乙酸酐 、 potassium carbonate 、 溶剂黄146 、 三乙胺 、 N,N-二异丙基乙胺 、 亚硝酸异戊酯 作用下， 以 二氯甲烷 、 甲苯 为溶剂， 135.0 ℃ 、1.5 MPa 条件下， 反应 27.0h， 生成 4-氮杂吲唑-6-甲酸乙酯
  参考文献：
  名称：

  [EN] PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS
  [FR] COMPOSÉS DE PYRAZOLOPIPÉRIDINE EN TANT QU'ANTAGONISTES DE RÉCEPTEUR CCR1

  摘要：

  揭示了一种公式（I）的化合物，可用于治疗多种通过CCR1活性介导或维持的疾病和紊乱，包括自身免疫性疾病，如类风湿性关节炎和多发性硬化症。还公开了制备方法和使用方法。

  公开号：

  WO2012087782A1
• 作为产物：
  描述：

  5-溴-2-氯-3-硝基吡啶 在 盐酸 、 水 、 铁粉 、 sodium hydride 作用下， 以 industrial methylated spirit 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 22.5h， 生成 2-甲基-3-氨基-5-溴吡啶
  参考文献：
  名称：

  [EN] N2-PYRAZOLOSPIROKETONE ACETYL-COA CARBOXYLASE INHIBITORS
  [FR] INHIBITEURS DE N2-PYRAZOLOSPIROCÉTONE ACÉTYL-COA CARBOXYLASE

  摘要：

  该发明提供了化合物(I)的结构或该化合物的药用盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的应用。

  公开号：

  WO2011058473A1

文献信息

• [EN] FUSED PYRAZOLE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLE CONDENSÉS UTILISÉS EN TANT QU'INHIBITEURS DE JAK
  申请人：ALMIRALL SA

  公开号：WO2017220431A1

  公开（公告）日：2017-12-28

  Novel fused pyrazole derivatives of Formula (I) are disclosed; as well as process for their preparation, pharmaceutical compositions comprising them and their use in therapy as inhibitors of Janus Kinases (JAK).

  公开了式（I）的新型融合吡唑衍生物；以及它们的制备方法，包含它们的药物组合物以及它们作为Janus激酶（JAK）抑制剂在治疗中的用途。
• Efficient and highly selective boron-doped carbon materials-catalyzed reduction of nitroarenes
  作者：Yangming Lin、Shuchang Wu、Wen Shi、Bingsen Zhang、Jia Wang、Yoong Ahm Kim、Morinobu Endo、Dang Sheng Su

  DOI：10.1039/c5cc01963j

  日期：——

  Boron-doped carbon materials are demonstrated to be excellent catalysts in nitroarene reduction reactions.

  硼掺杂的碳材料被证明在硝基芳烃还原反应中是优秀的催化剂。
• 咪唑酮类衍生物、其药物组合物和用途
  申请人：北京富龙康泰生物技术有限公司

  公开号：CN104411706B

  公开（公告）日：2016-11-16

  本申请涉及咪唑酮类化合物、其药学可接受的盐、溶剂化物、多晶形物或前药，还涉及包含上述物质的药物组合物和用于预防和治疗蛋白激酶相关性疾病如癌症、代谢疾病、心血管疾病等的用途。
• [EN] PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE COMPOUNDS AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS<br/>[FR] COMPOSÉS DE PYRAZOLO[1,5-A]PYRIMIDINYL CARBOXAMIDE ET LEUR UTILISATION DANS LE TRAITEMENT DE TROUBLES MÉDICAUX
  申请人：LYSOSOMAL THERAPEUTICS INC

  公开号：WO2017176960A1

  公开（公告）日：2017-10-12

  The invention provides substituted pyrazolo[1,5-a]pyrimidinyl carboxamide and related organic compounds, compositions containing such compounds, medical kits, and methods for using such compounds and compositions to treat medical disorders, e.g., Gaucher disease, Parkinson's disease, Lewy body disease, dementia, or multiple system atrophy, in a patient. Exemplary substituted pyrazolo[1,5-a]pyrimidinyl carboxamide compounds described herein include 2-heterocyclyl-4-alkyl-pyrazolo[1,5-a]pyrirnidine-3-carboxarnide compounds and variants thereof.

  本发明提供了取代的吡唑[1,5-a]嘧啶基甲酰胺及其相关有机化合物，包含此类化合物的组合物，医疗包，以及使用此类化合物和组合物治疗医疗障碍的方法，例如，戈谢病，帕金森病，路易体病，痴呆症或多系统萎缩症。所述的代表性的取代吡唑[1,5-a]嘧啶基甲酰胺化合物包括2-杂环基-4-烷基-吡唑[1,5-a]嘧啶-3-甲酰胺化合物及其变体。
• N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors
  申请人：BAGLEY SCOTT WILLIAM

  公开号：US20110111046A1

  公开（公告）日：2011-05-12

  The invention provides a compound of Formula (I) or a pharmaceutically acceptable salt of the compound, wherein R 1 , R 2 , R 3 and R 4 are as described herein; pharmaceutical compositions thereof; and the use thereof in treating diseases, conditions or disorders modulated by the inhibition of an acetyl-CoA carboxylase enzyme(s) in an animal.

  该发明提供了化合物I的化合物或其药用可接受的盐，其中R1、R2、R3和R4如本文所述；以及其药物组合物；以及在治疗受乙酰辅酶A羧化酶抑制调节的动物疾病、症状或紊乱中的使用。